VTGN Stock Price, VistaGen Therapeutics Quote, Chart

Market Summary

USD4.83+0.05

Market Closed

1.05%

VTGN Stock Price

View Fullscreen

VTGN RSI Chart

VTGN Valuation

Market Cap

130.5M

Price/Earnings (Trailing)

-4.07

Price/Sales (Trailing)

78.97

EV/EBITDA

-0.13

Price/Free Cashflow

-5

VTGN Price/Sales (Trailing)

VTGN Profitability

EBT Margin

-1939.87%

Return on Equity

-26.01%

Return on Assets

-24.47%

Free Cashflow Yield

-19.99%

VTGN Fundamentals

VTGN Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

-68.89%

Rev. Growth (Qtr)

-68.89%

VTGN Earnings

Earnings (TTM)

-32.1M

Earnings Growth (Yr)

34.95%

Earnings Growth (Qtr)

3.61%

Breaking Down VTGN Revenue

Last 7 days

3.9%

Last 30 days

15.8%

Last 90 days

0.4%

Trailing 12 Months

13.9%

How does VTGN drawdown profile look like?

VTGN Financial Health

Current Ratio

30.76

VTGN Investor Care

Shares Dilution (1Y)

269.66%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	1.7M
2022	1.1M	1.1M	1.6M	0
2021	1.1M	1.4M	1.5M	1.5M
2020	0	0	1.6M	1.9M
2017	1.3M	0	0	0
2016	0	0	0	0
2015	2.7M	0	0	0
2014	709.7K	1.2M	1.7M	2.2M
2013	200.4K	0	0	0
2012	1.3M	987.7K	671.7K	669.4K
2011	0	0	1.9M	1.5M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of VistaGen Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 29, 2023	adler reid g.	acquired	286	1.717	167	chf corp devel off, gen couns
Dec 29, 2023	singh shawn	acquired	286	1.717	167	chief executive officer
Aug 07, 2023	commodore capital lp	bought	17,961,100	23.153	775,756	-
Jun 30, 2023	dotson jerrold duane	acquired	265	1.5895	167	vp, cfo
Jun 30, 2023	singh shawn	acquired	265	1.5895	167	chief executive officer
Jun 30, 2023	adler reid g.	acquired	265	1.5895	167	chief legal officer
Dec 30, 2022	dotson jerrold duane	acquired	438	0.0876	5,000	vp, cfo and secretary
Dec 30, 2022	singh shawn	acquired	438	0.0876	5,000	chief executive officer
Aug 18, 2022	gin jerry b	bought	17,870	0.1787	100,000	-

Which funds bought or sold VTGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Jan 12, 2024	GPS Wealth Strategies Group, LLC	unchanged	-	-844	43,387	0.01%
Feb 15, 2023	PERSONAL CAPITAL ADVISORS CORP	new	-	2,791	2,791	-%
Nov 15, 2022	Pinz Capital Management, LP	sold off	-100	-17,000	-	-%
May 16, 2022	Amalgamated Financial Corp.	new	-	38,000	38,000	-%
May 16, 2022	Parametric Portfolio Associates LLC	reduced	-65.66	-58,000	16,000	-%
Aug 13, 2021	QS Investors, LLC	new	-	561,000	561,000	0.01%

Are Funds Buying or Selling VTGN?

Are funds buying VTGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VTGN

No. of Funds

Unveiling VistaGen Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	9.9%	2,797,588	SC 13G
Feb 14, 2024	citadel advisors llc	5.6%	6	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	3.0%	822,334	SC 13G/A
Feb 14, 2024	great point partners llc	9.99%	2,792,927	SC 13G/A
Feb 13, 2024	vanguard group inc	6.79%	1,834,512	SC 13G
Oct 16, 2023	tcg crossover gp ii, llc	7.5%	2,033,012	SC 13G
Oct 16, 2023	citadel advisors llc	5.6%	6	SC 13G
Oct 16, 2023	biotechnology value fund l p	5.2%	1,437,104	SC 13G
Oct 12, 2023	great point partners llc	9.99%	2,792,927	SC 13G
Oct 06, 2023	commodore capital lp	9.9%	2,367,884	SC 13G/A

Recent SEC filings of VistaGen Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	DEF 14A	DEF 14A
Apr 05, 2024	PRE 14A	PRE 14A
Apr 01, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Feb 29, 2024	EFFECT	EFFECT

Peers (Alternatives to VistaGen Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

VistaGen Therapeutics Inc News

Latest updates

VistaGen Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3
Revenue	-53.9%	411,400	892,500	310,100	38,900	357,900	358,000	354,100	442,000	313,600	334,000	-	1,250,000	-	-	-	-	-	-	-	-	-
Operating Expenses	-50.0%	8,295,400	16,596,800	20,083,200	16,732,000	10,897,000	13,158,000	8,101,000	6,661,000	5,612,900	3,627,700	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	1.5%	3,757,800	3,702,300	4,791,800	4,498,000	3,118,000	3,221,000	2,643,000	1,770,000	2,116,800	1,269,500	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-64.8%	4,537,600	12,894,500	15,291,400	12,234,000	7,779,000	9,937,000	5,458,000	4,891,000	3,496,100	2,358,200	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	54.5%	-18.29	-40.22	-56.01	-42.94	-24.56	-21.74	-15.52	-16.35	-11.91	-12.44	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	25050.8%	1,534,200	6,100	2,300	5,000	5,000	5,000	5,000	8,000	600	-3,900	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	5,500	-	-	-	3,000	-	-	200	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	63.7%	-6,349,800	-17,483,200	-19,770,800	-16,688,000	-10,534,000	-12,795,000	-7,742,000	-6,211,000	-5,298,700	-3,297,600	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	51.9%	-19.40	-40.31	-56.14	-43.07	-24.66	-21.83	-15.62	-16.46	-11.99	-12.52	-	-	-	-	-	-	-	-	-	-	-
Net Income	63.7%	-6,349,800	-17,483,200	-19,776,300	-16,688,000	-10,534,000	-12,795,000	-7,745,000	-6,211,000	-5,298,700	-3,297,800	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	51.9%	-19.40	-40.32	-56.15	-43.07	-24.66	-21.84	-15.62	-16.46	-11.99	-12.52	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	72.3%	-4,535,400	-16,365,200	-16,143,400	-15,588,600	-12,045,400	-11,500,100	-6,322,800	-5,307,400	-4,988,600	1,003,700	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	210.6%	131	42.00	15.00	21.00	30.00	41.00	59.00	75.00	91.00	100	104	108	109	20.00	6.00	6.00	5.00	9.00	13.00	14.00	8.00
Current Assets	227.9%	128	39.00	12.00	18.00	26.00	37.00	55.00	71.00	87.00	96.00	100	104	105	16.00	2.00	2.00	1.00	5.00	9.00	14.00	7.00
Cash Equivalents	236.5%	127	38.00	10.00	17.00	25.00	35.00	52.00	68.00	84.00	94.00	98.00	103	104	15.00	2.00	1.00	1.00	4.00	8.00	13.00	6.00
Net PPE	0.2%	0.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	18.8%	8.00	7.00	8.00	9.00	9.00	11.00	13.00	10.00	11.00	20.00	18.00	16.00	15.00	16.00	12.00	12.00	11.00	12.00	11.00	7.00	6.00
Current Liabilities	43.1%	4.00	3.00	4.00	5.00	4.00	6.00	9.00	6.00	6.00	8.00	6.00	4.00	3.00	3.00	3.00	28.00	3.00	4.00	3.00	3.00	2.00
Shareholder's Equity	245.9%	123	36.00	7.00	12.00	21.00	30.00	46.00	65.00	80.00	81.00	86.00	92.00	94.00	4.00	-	-	-	-	2.00	7.00	2.00
Retained Earnings	-1.9%	-346	-340	-333	-326	-314	-304	-287	-267	-250	-240	-227	-219	-213	-208	-205	-201	-198	-192	-187	-181	-175
Additional Paid-In Capital	24.7%	474	380	345	343	339	338	337	336	335	325	317	316	311	216	203	200	196	193	193	192	181
Shares Outstanding	237.1%	29.00	9.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	6.00	3.00	3.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	31.00	-	-	-	537	-	-	-	51.00	-	-	-	45.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	26.7%	-4,535	-6,189	-7,890	-7,472	-9,933	-16,340	-15,968	-15,588	-12,045	-11,449	-6,172	-5,281	-4,988	1,004	-2,806	-2,579	-4,279	-4,136	-4,761	-3,557	-3,907
Share Based Compensation	-13.2%	507	584	569	602	746	1,032	957	1,402	724	765	590	490	730	411	675	732	1,632	394	1,063	924	735
Cashflow From Investing	-Infinity%	-32.30	-	-	-528	-12.50	-24.40	-175	-100*	100*	-50.50	-149	-25.50	-151	-98.80	-	-	-	-	-	-4.20	-
Cashflow From Financing	173.6%	93,519	34,176	876	-398	-304	-334	-5.50	24.00	2,119	7,350	991	4,085	94,071	12,949	2,998	2,871	1,271	-87.90	-41.80	10,376	2,361

VTGN Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 411,400		$ 866,700
Sublicense and other revenue		$ 179,600		$ (402,900)
Operating expenses:
Research and development	4,537,600	6,854,000	12,585,400	35,039,800
General and administrative	3,757,800	3,092,100	9,943,300	11,586,200
Total operating expenses	8,295,400	9,946,100	22,528,700	46,626,000
Loss from operations	(7,884,000)	(9,766,500)	(21,662,000)	(47,028,900)
Other income, net:
Interest income, net	1,534,200	5,300	1,823,900	13,700
Loss before income taxes	(6,349,800)	(9,761,200)	(19,838,100)	(47,015,200)
Income taxes	0	0	(2,500)	(5,500)
Net loss and comprehensive loss	$ (6,349,800)	$ (9,761,200)	$ (19,840,600)	$ (47,020,700)
Basic and diluted net loss per common share (in dollars per share)	$ (0.22)	$ (1.42)	$ (1.27)	$ (6.82)
Weighted average common shares outstanding, basic and diluted (in shares)	29,388,085	6,894,603	15,632,451	6,891,641

VTGN Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Assets, Current [Abstract]
Cash and cash equivalents	$ 126,559,200	$ 16,637,600
Prepaid expenses and other current assets	1,480,300	802,700
Deferred contract acquisition costs - current portion	74,500	67,100
Total current assets	128,114,000	17,507,400
Property and equipment, net	445,100	507,300
Right-of-use asset - operating lease	1,933,600	2,260,300
Deferred offering costs	325,700	495,700
Deferred contract acquisition costs - non-current portion	148,700	217,600
Security deposits	100,900	100,900
Total assets	131,068,000	21,089,200
Current liabilities:
Accounts payable	1,737,000	2,473,100
Accrued expenses	129,300	787,400
Deferred revenue - current portion	1,762,800	714,300
Operating lease obligation - current portion	533,500	485,600
Financing lease obligation - current portion	1,900	1,700
Total current liabilities	4,164,500	4,567,400
Non-current liabilities:
Deferred revenue - non-current portion	1,899,400	2,314,600
Operating lease obligation - non-current portion	1,713,300	2,119,800
Financing lease obligation - non-current portion	6,000	7,400
Total liabilities	7,783,200	9,009,200
Commitments and Contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and March 31, 2023; no shares outstanding at December 31, 2023 and March 31, 2023	0	0
Common stock, $0.001 par value; 325,000,000 shares authorized at December 31, 2023 and March 31, 2023; 27,029,731 and 7,315,583 shares issued at December 31, 2023 and March 31, 2023, respectively	27,000	7,300
Additional paid-in capital	473,918,200	342,892,500
Treasury stock, at cost, 4,522 shares of common stock held at December 31, 2023 and March 31, 2023	(3,968,100)	(3,968,100)
Accumulated deficit	(346,692,300)	(326,851,700)
Total stockholders’ equity	123,284,800	12,080,000
Total liabilities and stockholders’ equity	131,068,000	21,089,200
Collaborative Arrangement [Member]
Current liabilities:
Note payable	$ 0	$ 105,300

About VistaGen Therapeutics Inc

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

CEO	Mr. Shawn K. Singh J.D.
WEBSITE	vistagen.com
INDUSTRY	Biotechnology
EMPLOYEES	32

VistaGen Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for VistaGen Therapeutics Inc? What does VTGN stand for in stocks?

VTGN is the stock ticker symbol of VistaGen Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of VistaGen Therapeutics Inc (VTGN)?

As of Tue Apr 23 2024, market cap of VistaGen Therapeutics Inc is 130.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VTGN stock?

You can check VTGN's fair value in chart for subscribers.

What is the fair value of VTGN stock?

You can check VTGN's fair value in chart for subscribers. The fair value of VistaGen Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of VistaGen Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VTGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is VistaGen Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VTGN is over valued or under valued. Whether VistaGen Therapeutics Inc is cheap or expensive depends on the assumptions which impact VistaGen Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VTGN.

What is VistaGen Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, VTGN's PE ratio (Price to Earnings) is -4.07 and Price to Sales (PS) ratio is 78.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VTGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on VistaGen Therapeutics Inc's stock?

In the past 10 years, VistaGen Therapeutics Inc has provided -0.104 (multiply by 100 for percentage) rate of return.